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1. INTRODUCTION 
Steroid hormones exert their glucocorticoid acti- 
vity by binding reversibly to a receptor protein in 
the cytoplasm of target cells [ 1,2]. We have shown 
[3] that Ca2+ inhibit the rate of association of de- 
xamethasone, a semi-synthetic glucocorticoid, with 
the glucocorticoid receptor. The half-maximum ef- 
fect was seen at 0.3 PM free Ca2+, a concentration 
within the range (0. l- 1 PM) of fluctuations of free 
intracellular Ca2 + that occur in response to hor- 
monal stimulation in several cell types [4]. Many 
‘second messenger’ functions of calcium (e.g., con- 
trol of protein phosphorylation) are exerted 
through calmodulin, a ubiquitous thermostable 
protein that serves as a multifunctional intracellular 
calcium receptor [5-81. Thus, the effect of calcium 
on glucocorticoid-receptor binding might be me- 
diated by calmodulin, the more so as thermostable 
factor(s) and phosphorylation processes presuma- 
bly control glucocorticoid receptor activity 191. Such 
a mechanism has been proposed for the acetylcho- 
line receptor [lo]. Thus, we determined whether 
calmodulin antagonists influence dexamethasone 
binding to the glucocorticoid receptor. The antago- 
nists belonged to the class of antipsychotic pheno- 
thiazines, i.e., trifluoperazine (TFP) [ 11,121, mem- 
brane-active compounds, i.e., propranolol and SKF 
525A [ 131, microtubule inhibitors, i.e., vinblastine 
1141, and new calmodulin inhibitors, i.e., R 24571 
[151. 
ever, some of these and related drugs (SKF 550 and 
SKF 625A) competitively inhibit the binding of 
dexamethasone to its receptor. TFP, the most 
potent inhibitor, prevents induction of tyrosine 
aminotransferase by dexamethasone. Thus, cal- 
modulin inhibitors may act as glucocorticoid antag- 
onists, not via calmodulin inhibition but through a 
direct interaction with the glucocorticoid receptor. 
2. MATERIALS AND METHODS 
We show here that the calcium effect is not pre- 
vented by such antagonists of calmodulin. How- 
* To whom all correspondence should be addressed 
Frozen pellets of HTC cells grown and harvested 
as in [16] were disrupted (tight-fitting Dounce ho- 
mogeniser, 70 strokes) in buffer (3-5 x lo7 cells/ 
ml) containing 20 mM N-[tris-(hydroxymethyl)- 
methyl]-glycine (Tricine, Calbiochem, San Diego 
CA) and 10 mM NazMoOq, pH 7.4 at 22°C. Par- 
ticles were removed by centrifugation at 15 000 
rev./min for 20 min (Sorvall SS-34 rotor) and then 
at 49 000 rev./min for 60 min (Spinco 50Ti rotor). 
The final supernatant (cytosol) was frozen at 
- 80°C. Cytosol aliquots (0.1 ml) were incubated in 
triplicate at 0°C in the homogenisation buffer (final 
vol. 0.4 ml), in the presence of [3H]dexamethasone, 
without or with one of the drugs listed below. At 
the end of the incubation period, 0.2 ml aqueous 
charcoal suspension (50 mg/ml) containing dex- 
tran (5 mg/ml) was added. Incubations were agitated 
for 10 s and centrifuged to remove free steroid. 
Radioactivity in 0.25 ml supernatant was counted in 
picofluor (Packard, Warrenville IL) using a Ber- 
thold (Wildbad) scintillation counter (efficiency 
58%) to determine macromolecule-bound steroid. 
Receptor binding was calculated by subtracting 
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Effect of calmodulin antagonists and related compounds on dexamethasone binding to the 
glucocorticoid receptor 
Drug Effect on dexamethasone binding 
Inhibition of Equilibrium 
initial rate (%)” Ki, W) 
Effect on calmodulin _ 
App. Kib 
(N) Ref. 
Trifluoperazine 75 5 6 
SKF 550 51 7 n.d. 
SKF 625A 23 19 n.d. 
Vinblastine 13 29 36 
Propranolol 55 45 180 
SKF 525A 53 88 130 







a At the drug concentrations given in fig. IA 
b Apparent equilibrium binding constant 1221 or concentration of drug that produces 50% 
inhibition ofcalmodulin-mediated stimulation ofbrain phosphodiesterase [ 131 or erythrocyte 
Ca2+-transport ATPase [ 141 
nd. = not described 
The initial rate of dexamethasone association with the receptor was determined by measuring 
binding after 30 min incubation. The equilibrium inhibition constants are means from at least 
2 expt performed as in fig. IA. The effects of the drugs on calmodulin are taken from the 
references cited 
non-specific binding determined in parallel incu- 
bations containing 0.2 mM HgC12. Binding assays 
involving SKF 525A were performed by hydroxyl- 
apatite precipitation of the receptor ]3] instead of 
charcoal adsorption of free steroid because this 
compound bound to charcoal. 
Trifluoperazine, SKF 550, SKF 525A, and SKF 
625A were generous gifts of Smith, Kline and 
French (Philadelphia PA). Dexamethasone (9~ 
fluoro- 16a-methyl- 1 l/3, 17,2 I-trihydroxy- 1,4-preg- 
nadiene-3,20-dione) was a generous gift of Merck, 
Sharp and Dohme (Rahway NJ). Propranolol was 
obtained from ICI (Macclestield), vinblastine from 
E. Lilly (Indianapolis IN), R 24571 from Janssen 
Pharmaceutics (Beerse) and [3H]dexamethasone 
(46 Ci/mmol) from the Radiochemical Centre, 
Amersham. 
3. RESULTS AND DISCUSSION 
Rat hepatoma tissue culture (HTC) cells contain 
steroid receptors that are specific for glucocorti- 
coids and respond to dexamethasone by increased 
22 
tyrosine aminotransferase activity [ 11. HTC cytosol 
was incubated with [3H]dexamethasone and speci- 
fic binding was determined after 30 min at 0” C as a 
measure of the initial rate of association of the 
steroid with the receptor. Under these conditions, 
binding is decreased when calcium is added to the 
incubation and is increased by calcium chelating 
agents such as EDTA or ethylene glycol bis-(P- 
amino ethyl ether) N, N,N’, N’-tetraacetic acid 
(EGTA) [3]. According to our hypothesis, cal- 
modulin antagonists were expected to stimulate the 
binding by preventing endogenous calcium from 
exerting its inhibitory effect [3]. However, none of 
the antagonists tested stimulated the rate of bind- 
ing; instead, some inhibited binding by up to 75% 
(table 1). 
Calmodulin antagonists are thought to act by bind- 
ing to a lipophilic region of calmodulin exposed 
upon interaction of this protein with calcium [5-8, 
11,12,17,18]. Perhaps inhibition of dexametha- 
sone binding by these drugs resulted from a per- 
turbation of the hydrophobic [ 191 steroid-bind- 
ing site on the glucocorticoid receptor rather than 
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Competitor pM 
A o None 
I 
l R 24571 ; 
v SKF 525A 250 
v SKF 625A 125 
0 Vinblastine 100 
A Trifluoperazine 0.5 
l SKF 550 
A Propranolol 2Go 
1 
5 10 15 
1 /FREE (M-lx lo+) 
B 
l [JH]-Dexamethasone (7.2 nM ) 








TFP CONCENTRATION ( MxlO’) 
F&l. Competitive inhibition of [3H]dexamethasone binding to the glucocorticoid receptor by calmodulin antagonists and 
related drugs. 
(A) Aliquots of HTC ccl cytosol were incubated in triplicate at 0°C as in table 1 except hat 1 mM EDTA was added to the 
buffer and the [3H]dexamethasone concentration was varied, without or with fixed concentrations of the drugs as 
indicated. After 16 h, specific dexamethasone binding was determined by charcoal assay and the results presented as 
double-reciprocal plots [20]. 
(B) The experiments were performed as above using fixed concentrations of [3H]dexamethasone and varying concentra- 
tions of TFP. The data are plotted according to Dixon [2 11 and yield K, 7.7 PM for TFP. 
from an effect on calmodulin. If so, the antagonists 
should inhibit dexamethasone binding even in the 
absence of free calcium. This was the case since 
EDTA did not prevent the antagonists from de- 
pressing dexamethasone binding to its receptor. 
To further investigate this phenomenon, binding 
experiments were conducted at equilibrium (16 h, 
O’C) by using various (3H]dexamethasone concen- 
trations with fixed concentrations of the inhibitors 
and in the presence of EDTA. Double-reciprocal 
plots of the data (fig.lA) were compatible with 
competitive inhibition either at, or close to, the ster- 
oid-binding site [20]. This alternative was investi- 
gated in experiments designed according to 1211 
using the most potent inhibitor, TFP. The plots 
were linear (Iig.lB), which is consistent with a 
purely competitive phenomenon. If this effect were 
unrelated to calmodulin inhibition then the potency 
of the drugs as calmodulin antagonistst might not 
match their potency as inhibitors of dexamethasone 
binding. A comparison of the respective inhibition 
constants (table I), albeit suggestive of a discre- 
pancy, did not give a definite answer. We therefore 
used R 2457 1, a novel and more specific calmodulin 
antagonist [ 151 that has an affinity for calmodulin 3 
orders of magnitude greater than TFP 1221. At a 
23 
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concentration (50 nM) that saturates calmodulin R 
24571 did not influence the rate of dexamethasone 
binding to its rece 
10 PM) of free Ca Y 
tor over a wide range (10 nM- 
+ (not shown). Furthermore, R 
2457 1 at the highest concentration compatible with 
solubility (3 PM) did not influence dexamethasone 
binding whether in absence (table 1) or presence 
(fig.lA) of EDTA. We also tested other membrane- 
active compounds, SKF 550 and SKF 625A (potent 
inhibitors of the extraneuronal catecholamine up- 
take process 1231). Each of the drugs depressed 
cell-free dexamethasone binding (table 1), appar- 
ently through a competitive inhibition mechanism 
(fig. 1A). 
These results, together with the lack of a calcium 
requirement for inhibition of dexamethasone bind- 
ing by these drugs, make it unlikely that calmod- 
ulin mediates the effect of calcium on the gluco- 
corticoid receptor. We conclude that several cal- 
modulin antagonists, including the potent com- 
pound TFP, inhibit glucocorticoid action by com- 
peting with the hormone for the steroid-binding 
site. Consistent with this interpretation TFP in- 
hibited the induction by dexamethasone of tyrosine 
aminotransferase in HTC cells without affecting 














t: 0 10 20 30 LO 
TIME(h) 
Fig.2. Inhibition of TFP of tyrosine aminotransferase 
induction by dexamethasone in HTC cells. Duplicate 
cultures of HTC cells in serum free medium (1) were 
exposed to 25 nM dexamethasone or to the vehicle, 
ethanol (0.25%, v/v). Half of each culture also received 10 
PM TFP. Incubations were kept at 37°C and aliquots 
removed at the times indicated for determination of 
24 
tyrosine aminotransferase activity [I]. 
Inhibition of biochemical processes in intact cells 
exposed to TFP has often been taken as evidence 
for an involvement of calmodulin 124-261. Our 
finding that TFP and functionally related drugs 
interfere with glucocorticoid receptor action draws 
the attention to an alternate mechanism because 
glucocorticoid hormones control the activity of a 
number of enzymes [2]. The antipsychotic effect of 
TFP is not related to inhibition of calmodulin 
127,281, nor is its capability to reduce ATP levels in 
lymphocytes [29]. The potential antiglucocorticoid 
activity of TFP adds a new facet to the pharmaco- 
logic properties of phenothiazines and could give a 
clue to some of their side-effects 1301. Likewise, 
interaction of membrane-active compounds with the 
intracellular glucocorticoid receptor might account 
for hitherto unexplained observations uch as the 
inhibition by propranolol of tyrosine aminotrans- 
ferase induction by dexamethasone in chick em- 
bryo liver cells [3 11. 
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